Advertisement
Singapore markets closed
  • Straits Times Index

    3,460.82
    -0.34 (-0.01%)
     
  • S&P 500

    5,555.74
    -8.67 (-0.16%)
     
  • Dow

    40,358.09
    -57.35 (-0.14%)
     
  • Nasdaq

    17,997.35
    -10.22 (-0.06%)
     
  • Bitcoin USD

    66,479.18
    -413.45 (-0.62%)
     
  • CMC Crypto 200

    1,370.34
    +4.45 (+0.33%)
     
  • FTSE 100

    8,146.33
    -21.04 (-0.26%)
     
  • Gold

    2,414.60
    +7.30 (+0.30%)
     
  • Crude Oil

    77.43
    +0.47 (+0.61%)
     
  • 10-Yr Bond

    4.2390
    -0.0210 (-0.49%)
     
  • Nikkei

    39,154.85
    -439.54 (-1.11%)
     
  • Hang Seng

    17,311.05
    -158.31 (-0.91%)
     
  • FTSE Bursa Malaysia

    1,621.14
    -8.54 (-0.52%)
     
  • Jakarta Composite Index

    7,262.76
    -51.10 (-0.70%)
     
  • PSE Index

    6,753.12
    0.00 (0.00%)
     

Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade

The most recent trading session ended with Abbott (ABT) standing at $103.45, reflecting a -0.22% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.77%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.95%.

The the stock of maker of infant formula, medical devices and drugs has fallen by 0.39% in the past month, lagging the Medical sector's gain of 1.49% and the S&P 500's gain of 3.71%.

The investment community will be paying close attention to the earnings performance of Abbott in its upcoming release. The company is predicted to post an EPS of $1.10, indicating a 1.85% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $10.35 billion, up 3.78% from the year-ago period.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.62 per share and a revenue of $41.66 billion, signifying shifts of +4.05% and +3.86%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Abbott possesses a Zacks Rank of #3 (Hold).

From a valuation perspective, Abbott is currently exchanging hands at a Forward P/E ratio of 22.45. For comparison, its industry has an average Forward P/E of 23.95, which means Abbott is trading at a discount to the group.

Meanwhile, ABT's PEG ratio is currently 2.49. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. ABT's industry had an average PEG ratio of 2.16 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 139, finds itself in the bottom 45% echelons of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research